FDA gets new tools to ban fake supplements and dangerous nootropics
S. 3797 — Prohibiting Tianeptine and Other Dangerous Products Act of 2026 · Filed by Richard Durbin (D-IL) · 1 cosponsor · Introduced Feb 5, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill adds two new prohibited acts to federal dietary supplement law: (1) selling products labeled as dietary supplements that do not legally qualify as dietary supplements, and (2) selling dietary supplements made with help from people barred from the industry. It gives FDA authority to exclude such products at the border and seize them domestically. The bill targets products like tianeptine (a nootropic sold as a supplement but functioning as a drug) that evade FDA oversight by misclassification.
Why we flagged it
The bill closes a regulatory gap by prohibiting mislabeled products and strengthening FDA enforcement tools. It is a straightforward public-health measure targeting deceptive marketing and unsafe manufacturing practices in the dietary supplement market.
What the text implies
- Tianeptine (a nootropic/mood-enhancing substance sold as 'gas station heroin') will face enforcement action; this may disrupt a small but growing online/retail market for the product.
- The definition of 'dietary supplement' under Section 201(ff) becomes the operative boundary; products that fail that definition are now explicitly prohibited, which may catch borderline nootropics, adaptogens, or other substances marketed ambiguously.
- Debarred persons (those previously sanctioned by FDA) cannot participate in supplement manufacturing; this may reduce recidivism among bad actors but also increases compliance burden on manufacturers to vet suppliers and partners.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
Ordinary consumers gain protection against products marketed as unregulated dietary supplements when they are actually drugs or made by barred actors. The bill closes a regulatory loophole that allows dangerous substances to reach consumers without FDA safety review. No offsetting cost to citizens is apparent.
Named in the bill
FDA (Food and Drug Administration), Federal Food, Drug, and Cosmetic Act, Section 201(ff) (dietary supplement definition), Section 301 (prohibited acts), Section 306 (debarment), Tianeptine
Where it stands
1 cosponsor: 1 Democrats.
- Feb 5, 2026 — Introduced · Congress.gov: “Introduced in Senate”
- Feb 5, 2026 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S512)”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Mar 2026 to Mar 2026. Those filings disclosed $90,000 in lobbying spend. A filing names 11 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 0% of bills with at least one filing.
Richard Durbin, the sponsor, reported $-29,800 in PAC receipts in the 2026 cycle.
- Pharmavite LLC — $90,000 on 1 filing
Lobbying Disclosure Act filings through May 6, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (1,399 characters) on Oct 21, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,388 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Mar 2026 to Mar 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through May 6, 2026 · page rendered 2026-10-21.
“FDA gets new tools to ban fake supplements and dangerous nootropics” QuorumCivic. https://share.quorumcivic.app/bill/119/s3797 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.